Search research articles
Contact Us
Filters
Showing results (11-20 of 57) with videos related to
Page
of 6
Sort By:
Novartis Foundation Symposium
|
July 30, 2005
Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies
Rashmi R Shah
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
August 13, 2005
Pharmacogenetics in drug regulation: promise, potential and pitfalls
Rashmi R Shah
Drug Safety
|
February 10, 2017
Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
Rashmi R Shah
Clinical Genitourinary Cancer
|
August 16, 2016
Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer 2016
Rashmi R Shah
Drug Safety
|
August 19, 2016
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R Shah
Drug Safety
|
February 6, 2004
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing
Rashmi R Shah
British Journal of Clinical Pharmacology
|
August 14, 2012
Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?
Rashmi R Shah
Drug Safety
|
February 5, 2005
Drugs, QT interval prolongation and ICH E14: the need to get it right
Rashmi R Shah
Drug Safety
|
October 20, 2005
Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead
Rashmi R Shah
Journal of Clinical Pharmacy and Therapeutics
|
October 13, 2018
Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity?
Rashmi R Shah
Page
of 6
Search research articles
Search
Showing results (11-20 of 57) with videos related to
Sort By:
Page
of 6
Novartis Foundation Symposium
|
July 30, 2005
Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies
Rashmi R Shah
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
August 13, 2005
Pharmacogenetics in drug regulation: promise, potential and pitfalls
Rashmi R Shah
Drug Safety
|
February 10, 2017
Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
Rashmi R Shah
Clinical Genitourinary Cancer
|
August 16, 2016
Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer 2016
Rashmi R Shah
Drug Safety
|
August 19, 2016
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R Shah
Drug Safety
|
February 6, 2004
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing
Rashmi R Shah
British Journal of Clinical Pharmacology
|
August 14, 2012
Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?
Rashmi R Shah
Drug Safety
|
February 5, 2005
Drugs, QT interval prolongation and ICH E14: the need to get it right
Rashmi R Shah
Drug Safety
|
October 20, 2005
Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead
Rashmi R Shah
Journal of Clinical Pharmacy and Therapeutics
|
October 13, 2018
Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity?
Rashmi R Shah
Page
of 6